Constellation Energy Corporation vs Heron Therapeutics Inc — how do they compare? Constellation Energy Corporation trades at $258 (market cap $91.57B), while Heron Therapeutics Inc trades at $0.43 (market cap $82.52M). The key difference: Constellation Energy Corporation is far larger — about 1109.7× Heron Therapeutics Inc's market cap, and Constellation Energy Corporation pays a 0.67% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CEG | HRTX | |
|---|---|---|
Market Cap | $91.57B | $82.52M |
Sector | Energy | Health |
52-Week High | $403.95 | $2.04 |
52-Week Low | $236.50 | $0.39 |
Enterprise Value | $113.24B | $180.42M |
Dividend Yield | 0.67% | — |
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →